These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
142 related items for PubMed ID: 18821278
1. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. Brodszky V, Pentek M, Gulacsi L. Scand J Rheumatol; 2008; 37(5):399-400. PubMed ID: 18821278 [No Abstract] [Full Text] [Related]
2. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA. Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542 [Abstract] [Full Text] [Related]
3. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis. Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M. J Med Econ; 2013 Apr; 16(4):479-89. PubMed ID: 23339434 [Abstract] [Full Text] [Related]
4. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, Puigventós-Latorre F, Borrero-Rubio JM, López-Vallejo JF. J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560 [Abstract] [Full Text] [Related]
5. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Scand J Rheumatol; 2005 Aug; 34(5):353-8. PubMed ID: 16234182 [Abstract] [Full Text] [Related]
6. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712 [Abstract] [Full Text] [Related]
7. Psoriatic arthritis patients doing better on infliximab than etanercept. Smith N, Gadsby K, Deighton C. Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216 [No Abstract] [Full Text] [Related]
8. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424 [Abstract] [Full Text] [Related]
10. [Treatment of psoriatic arthritis with TNF alpha-antagonists]. Antoni C, Manger B. Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399 [Abstract] [Full Text] [Related]
11. [Anti-TNF alpha in the treatment of psoriatic arthritis]. Claudepierre P, Wendling D, Cohen JD. Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610 [Abstract] [Full Text] [Related]
12. Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Migliore A, Bizzi E, Broccoli S, Laganà B. Clin Rheumatol; 2012 Jan; 31(1):193-4. PubMed ID: 22005889 [No Abstract] [Full Text] [Related]
13. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Migliore A, Bizzi E, Broccoli S, Laganà B. Clin Rheumatol; 2012 Jan; 31(1):133-7. PubMed ID: 21701796 [Abstract] [Full Text] [Related]
14. Errors noted in: re: Migliore A, Bizzi E, Broccoli S Laganà (2011). Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Published on line June 21st 2011. O'Regan C. Clin Rheumatol; 2011 Dec; 30(12):1647-8. PubMed ID: 21938451 [No Abstract] [Full Text] [Related]
15. Patient profiles in psoriatic disease: a case-based approach. Wiatrowski M, Furfaro N. Dermatol Nurs; 2007 Oct; Suppl():5-19; quiz 20-1. PubMed ID: 18341241 [Abstract] [Full Text] [Related]
16. [The role of biological agents in the treatment of psoriatic arthritis, literature review]. Koó E, Brodszky V, Péntek M, Ujfalussy I, Nagy MB, Gulácsi L. Orv Hetil; 2006 Oct 15; 147(41):1963-70. PubMed ID: 17120686 [Abstract] [Full Text] [Related]
17. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Girolomoni G, Abeni D. Arch Dermatol; 2001 Jun 15; 137(6):784-5. PubMed ID: 11405771 [No Abstract] [Full Text] [Related]
18. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA. Immunopharmacol Immunotoxicol; 2012 Aug 15; 34(4):548-60. PubMed ID: 22296031 [Abstract] [Full Text] [Related]
19. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark. Arthritis Rheum; 2010 Jan 15; 62(1):22-32. PubMed ID: 20039405 [Abstract] [Full Text] [Related]
20. [Biological treatment of psoriasis and psoriatic arthritis]. Kragballe K, Deleuran B. Ugeskr Laeger; 2008 Jun 09; 170(24):2148-50. PubMed ID: 18565300 [Abstract] [Full Text] [Related] Page: [Next] [New Search]